Overview

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) and/or diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Atorvastatin
Atorvastatin Calcium
Evacetrapib
Ezetimibe